Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perrigo CoPRGO -1.65%54 Days Sales Outstanding is 62.76 as of Jun. 2026, which is 10% below its 10-year median of 69.83. GuruFocus rates PRGO with a GF Score™ of 54/100 and a GF Value™ of $23.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Perrigo Co ranks better than 64.2% on this metric.
Perrigo Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was $704 Mil. Perrigo Co's Revenue for the
three
months ended in Jun. 2026 was $1,023 Mil.
Hence, Perrigo Co's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 62.76.
The historical rank and industry rank for Perrigo Co's Days Sales Outstanding or its related term are showing as below:
PRGO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.86 Med: 69.83 Max: 109.23
Current: 58.87
During the past 13 years, Perrigo Co's highest Days Sales Outstanding was 109.23. The lowest was 53.86. And the median was 69.83.
PRGO's Days Sales Outstanding is ranked better than 64.2% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.92
vs PRGO: 58.87
Perrigo Co's Days Sales Outstanding
increased
from Jun. 2025 (60.25) to Jun. 2026 (62.76).
Perrigo Co (NYSE:PRGO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Perrigo Co Days Sales Outstanding Related Terms
Perrigo Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Perrigo Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRGO vs ALVO, TRLV, ETON: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (PRGO) has a Days Sales Outstanding of 62.76 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Perrigo Co and its competitors. This is 10% below median its historical median of 69.83. Over the past decade, Perrigo Co's Days Sales Outstanding has ranged from 53.86 to 109.23. According to the industry distribution chart, Perrigo Co ranks #339 out of 947 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is Perrigo Co's Days Sales Outstanding too high?
Perrigo Co's current Days Sales Outstanding of 62.76 is 10% below median its 10-year median of 69.83. Over the past 10 years, this metric has ranged from a low of 53.86 to a high of 109.23. The Drug Manufacturers industry median Days Sales Outstanding is 71.92. Perrigo Co's value of 62.76 is 12.7% below this industry median. Based on the distribution chart, Perrigo Co ranks #339 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Perrigo Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's Days Sales Outstanding compare to ALVO and TRLV?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #339 out of 947 companies for Days Sales Outstanding. This puts Perrigo Co in the upper half of its industry. The industry median Days Sales Outstanding is 71.92. Perrigo Co's value of 62.76 is 12.7% below this benchmark. Historically, Perrigo Co's own Days Sales Outstanding has ranged from 53.86 to 109.23 over the past decade. While the company's 10-year median is 69.83 vs. the industry median of 71.92, Perrigo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.92, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current Days Sales Outstanding of 62.76 is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current Days Sales Outstanding is 62.76, which is 10% below median its own 10-year median of 69.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $23.78, compared to a current price of $14.34 — trading 39.7% below its estimated fair value. The current Days Sales Outstanding is 62.76, which is 10% below median its 10-year median of 69.83 and 12.7% below the Drug Manufacturers industry median of 71.92. Perrigo Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Perrigo Co (PRGO), the current Days Sales Outstanding is 62.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $14.34 is trading 39.7% below its estimated GF Value™ of $23.78.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
Days Sales Outstanding: 62.76 (10% below median its 10-year median of 69.83)
GF Value™: $23.78 vs. price of $14.34 (39.7% below fair value)
Industry Position: 12.7% below the Drug Manufacturers median (#339 of 947)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
54GF Score
Get the complete analysis for PRGO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
